Search results: Sage Journals

Restricted accessResearch articleFirst published April, 2025

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published January, 2020

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

Jiaqi Han, Desheng Xiao, Chongqing Tan [...]

Cancer Control

Open accessResearch articleFirst published 2026

Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated,RAS/BRAF-wild-type Metastatic Colorectal Cancer: A Retrospective Tissue-Microarray Analysis

Qinghua Wang, Hongjuan Zheng, Zhijian Zheng [...]

Cancer Control

Open accessResearch articleFirst published 2026

The impact of APC mutation on the efficacy of anti-EGFR therapy in metastatic colorectal cancer with RAS wild type: a retrospective analysis

Junkyu Kim, Changgon Kim, Ji Eun Shin [...]

Therapeutic Advances in Medical Oncology

Free accessResearch articleFirst published November, 2011

Increased Wild-Type N-Ras Activation by Neurofibromin Down-Regulation Increases Human Neuroblastoma Stem Cell Malignancy

Dan Han, Barbara A. Spengler, Robert A. Ross

Genes & Cancer

Open accessCase reportFirst published 2023

Anti-epidermal growth factor receptor treatment for patients with Neo RAS wild-type metastatic colorectal cancer: a case report of two cases

Kazuaki Harada, Satoshi Yuki, Yasuyuki Kawamoto [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol

Jinjie He, Yue Liu, Chengcheng Liu [...]

Technology in Cancer Research & Treatment

Restricted accessLetterFirst published October, 2022

Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer

Jacopo Giuliani

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2019

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Gemma Bruera, Silvia Massacese, Francesco Pepe [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2020

Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells

Yifan Duan, Xiaoyu Yin, Xiaorong Lai [...]

Technology in Cancer Research & Treatment

Restricted accessResearch articleFirst published April, 2025

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Mahmut Emre Yildirim, Nuri Karadurmuş, İlker Nihat Ökten [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published January, 2020

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

Jiaqi Han, Desheng Xiao, Chongqing Tan [...]

Cancer Control

Open accessResearch articleFirst published 2026

Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated,RAS/BRAF-wild-type Metastatic Colorectal Cancer: A Retrospective Tissue-Microarray Analysis

Qinghua Wang, Hongjuan Zheng, Zhijian Zheng [...]

Cancer Control

Open accessResearch articleFirst published 2026

The impact of APC mutation on the efficacy of anti-EGFR therapy in metastatic colorectal cancer with RAS wild type: a retrospective analysis

Junkyu Kim, Changgon Kim, Ji Eun Shin [...]

Therapeutic Advances in Medical Oncology

Free accessResearch articleFirst published November, 2011

Increased Wild-Type N-Ras Activation by Neurofibromin Down-Regulation Increases Human Neuroblastoma Stem Cell Malignancy

Dan Han, Barbara A. Spengler, Robert A. Ross

Genes & Cancer

Open accessCase reportFirst published 2023

Anti-epidermal growth factor receptor treatment for patients with Neo RAS wild-type metastatic colorectal cancer: a case report of two cases

Kazuaki Harada, Satoshi Yuki, Yasuyuki Kawamoto [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2023

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol

Jinjie He, Yue Liu, Chengcheng Liu [...]

Technology in Cancer Research & Treatment

Restricted accessLetterFirst published October, 2022

Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer

Jacopo Giuliani

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2019

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers

Gemma Bruera, Silvia Massacese, Francesco Pepe [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2020

Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells

Yifan Duan, Xiaoyu Yin, Xiaorong Lai [...]

Technology in Cancer Research & Treatment